Teva announces new Ajovy, Austedo data published

Teva announced that new data for Ajovy injection and Austedo tablets have appeared in an online supplement to Neurology. The data includes 23 abstracts that highlight a diverse set of data evaluating the efficacy and safety of Ajovy and Austedo. The abstracts were originally planned for presentation at the recently cancelled 2020 American Academy of Neurology, or AAN, annual meeting. In addition to the online supplement, the abstracts are also available through the AAN online abstracts website. The featured abstracts include new Ajovy and Austedo data, including results from an open-label extension of the FOCUS study, a Phase IIIb study that evaluated the efficacy and safety of quarterly and monthly treatment with Ajovy compared to placebo in adult patients with migraine and documented inadequate response to two to four classes of prior preventive treatments. Another analysis using the FDA Adverse Events Reporting System, or FAERS, provides patient and healthcare professional insight into the real-world experience with CGRP pathway-targeted therapies. In addition, new data is available from a long-term, open-label extension study which examined the safety of Austedo at higher doses beyond the approved maximum dose to treat chorea associated with Huntington's disease, as well as the long-term experience with Austedo in both younger and older patients with tardive dyskinesia.